Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04965935
Other study ID # 19-5342
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date July 15, 2021
Est. completion date June 15, 2024

Study information

Verified date May 2023
Source University Health Network, Toronto
Contact Vesta Lai, RN
Phone 416-340-4800
Email vesta.lai@uhn.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will be a randomized, double-blind, placebo-controlled clinical trial comparing the SGLT2 inhibitor dapagliflozin to placebo in 52 kidney transplant recipients (KTR) with or without pre-existing type 2 diabetes (T2D) or post-transplant diabetes mellitus (PTDM). The primary outcome of the trial is to determine if dapagliflozin is superior to placebo in reduction of blood pressure in KTR.


Description:

Kidney transplantation is the renal replacement therapy of choice for patients with end stage renal disease (ESRD). It has been well established that kidney transplantation improves patient survival and quality of life, and results in significant savings to the health care system. Despite the survival benefit conferred by transplantation, KTR still face a number of challenges, especially in patients with diabetes. First, KTR still have a higher risk of mortality than their age-matched counterparts without kidney disease. This mortality risk is even greater amongst KTR with diabetes. Furthermore, mortality from cardiovascular disease (CVD) continues to be an important problem after transplantation. Another major challenge faced by KTR is the continuing risk of developing graft failure over time. Unfortunately, in the subgroup of KTR with diabetes, the incidence of graft failure is 50% higher than the general kidney transplant recipient population, and recurrent diabetic kidney disease (DKD) occurs in almost half of allografts after transplantation. Current strategies in the management of graft dysfunction and chronic kidney disease (CKD) are focused on optimizing immunosuppression and control of hypertension and dyslipidemia. Accordingly, there is an important unmet need for cardio- and renoprotective strategies to address premature death and graft loss in the KTR population. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are glucose lowering agents that are effective in the treatment of T2D, resulting not only in improved glycemic control, but also weight loss, blood pressure and albuminuria reduction. Several clinical trials have shown significant benefits of SGLT2i on cardiovascular and renal outcomes. Given the glucose-dependent and independent effects of SGLT2i, as well as the accumulating evidence demonstrating cardiorenal protection in non-KTR, the use of these agents in KTR is attractive - especially since traditional renin-angiotensin-aldosterone system inhibitors are not effective. Moreover, the use of SGLT2i as a cardiorenal protective therapy may be of particular value in KTR given the high burden of comorbidities such as diabetes, CVD and hypertension, as well as the ongoing challenges of premature death and graft loss in this population. This study will be a randomized, double-blind, placebo-controlled clinical trial comparing the SGLT2 inhibitor dapagliflozin to placebo in 52 KTR with or without pre-existing T2D or PTDM. The primary outcome of the trial is to determine if dapagliflozin is superior to placebo in reduction of blood pressure in KTR. The secondary outcomes of this study include metabolic, vascular, renal and transplant-specific measures. These outcomes have been included to elucidate the potential mechanisms responsible for blood pressure lowering, and putative cardio- and renoprotective effects in KTR. Safety outcomes will also be assessed.


Recruitment information / eligibility

Status Recruiting
Enrollment 52
Est. completion date June 15, 2024
Est. primary completion date June 15, 2024
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: 1. Male or females >18 years old = 6months after kidney transplantation; 2. In patients with T2D or PTDM, HbA1c <12.0%; 3. eGFR =30 ml/min/1.73m^2 (as per the CKD-EPI equation); 4. BMI =45kg/m^2; 5. Blood pressure =160/90 and =90/60 at screening. Exclusion Criteria: 1. Diagnosis of type 1 diabetes; 2. Presence of severe peripheral vascular disease (i.e. prior amputation, gangrene, non-healing ulcer or ischemic rest pain); 3. Presence of acute coronary syndrome, stroke or transient ischemic attack in the 3 months prior to screening; 4. Prior episode of graft pyelonephritis in the 1 month prior to screening; 5. Episode of acute graft rejection in the 3 months prior to screening; 6. Initiation of a new immunosuppressive agent or discontinuation of an immunosuppressive agent in the 1 month prior to screening; 7. Untreated urinary or genital tract infection; 8. Severe hypoglycemia within 3 months of screening, or hypoglycemia unawareness; 9. Pre-menopausal women who are nursing, pregnant, or of child-bearing potential and not practicing an acceptable method of birth control; 10. Participation in another trial with an investigational drug within 30 days of informed consent; 11. Alcohol or drug abuse within 3 months prior to informed consent that would interfere with trial participation; 12. Any ongoing clinical condition that would jeopardize subject safety or study compliance based on investigator judgement. 13. Patients currently using antipsychotic medications. 14. Use of SGLT2 inhibitors within 1 month of starting the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Dapagliflozin 10 MG Oral Tablet
Dapagliflozin will be administered in a dose of 10 mg/day for 12 weeks.
Placebo Matching Dapagliflozin Oral Tablet
Placebo will be administered for 12 weeks.

Locations

Country Name City State
Canada Renal Physiology Laboratory Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
University Health Network, Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Systolic blood pressure SBP Change from baseline systolic blood pressure (SBP) at 12 weeks of treatment
Secondary Fasting plasma glucose Fasting plasma glucose Change from baseline fasting plasma glucose at 12 weeks of treatment
Secondary HbA1c HbA1c Change from baseline HbA1c at 12 weeks of treatment
Secondary Continuous home glucose monitoring Continuous home glucose monitoring Continuous glucose will be monitored for 14 days at 2 time intervals: 7 days prior to 7 days after drug administration (week -1 to1) and 7 days prior to 7 days after during drug discontinuation (week 11 to 13)
Secondary Arterial stiffness Measured using a Sphygmocor device Change from baseline arterial stiffness at 12 weeks of treatment
Secondary Systemic vascular resistance Measured using non-invasive cardiac output monitor (NICOM) Change from baseline systemic vascular resistance at 12 weeks of treatment
Secondary Glomerular Filtration Rate GFR Change from baseline GFR (based on plasma iohexol clearance) at 12 weeks of treatment
Secondary Estimated Glomerular Filtration Rate eGFR Change from baseline eGFR (based on CKD-EPI equation) at 12 weeks of treatment
Secondary Proximal tubular natriuresis Measured by fractional excretion of sodium and 24-hour urine collection Change from baseline proximal tubular natriuresis at 12 weeks of treatment
Secondary Albuminuria Albuminuria Change from baseline albuminuria at 12 weeks of treatment
Secondary Urinary and plasma concentration of oxidative stress markers Measured using ELISA Change from baseline oxidative stress markers at 12 weeks of treatment
Secondary Tubulointerstitial hypoxia Measured using a renal ultrasound (photoacoustic ultrasonography) Change from baseline tubulointerstitial hypoxia at 12 weeks of treatment
Secondary Calcineurin inhibitor (CNI) Levels CNI Change from baseline CNI at 12 weeks of treatment
Secondary Adverse Events (AEs) AEs Adverse events will be recorded from baseline throughout the study duration up to 13 weeks
See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Active, not recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A